A window of opportunity to control the bacterial pathogen Pseudomonas aeruginosa combining antibiotics and phages

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Torres Barceló, Clara ^a   Arias Sánchez, Flor I ^a   Vasse, Marie ^a   Ramsayer, Johan ^a   Kaltz, Oliver ^a   Hochberg, Michael E ^a,b,c  

^a INSTITUT DES SCIENCES DE L EVOLUTION   (France)

^b SANTA FE INSTITUTE   (United States)

^c Wissenshaftskolleg zu Berlin   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

STREPTOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CONTROL; BACTERIAL DENSITY; BACTERIAL GROWTH; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIOPHAGE; CONTROLLED STUDY; MICROBIOLOGICAL PARAMETERS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROCESS OPTIMIZATION; PSEUDOMONAS AERUGINOSA; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; PHYSIOLOGY; PSEUDOMONAS INFECTIONS; PSEUDOMONAS PHAGE; VIROLOGY;

BACTERIA (MICROORGANISMS); PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; BACTERIOPHAGES; DRUG RESISTANCE, BACTERIAL; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS PHAGES;

EID: 84907916701     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106628     Document Type: Article

References (44)

1. Rodriguez-Rojas A, Rodriguez-Beltran J, Couce A, Blazquez J (2013) Antibiotics and antibiotic resistance: A bitter fight against evolution. Int. J. Med. Microbiol. 303, 293-297.
2. Garcia-Quintanilla M, Pulido MR, Lopez-Rojas R, Pachon J, McConnell MJ (2013) Emerging therapies for multidrug resistant Acinetobacter baumannii. Trends Microbiol. 21, 157-163.
3. Allen HK, Levine UY, Looft T, Bandrick M, Casey TA (2013) Treatment, promotion, commotion: antibiotic alternatives in food-producing animals. Trends Microbiol. 21, 114-119.
4. Pirnay JP, Verbeken G, Rose T, Jennes S, Zizi M, et al. (2012) Introducing yesterday's phage therapy in today's medicine. Future Virol. 7, 379-390.
5. Wright A, Hawkins CH, Anggard EE, Harper DRA (2009) Controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34, 349-35.
6. Chan BK, Abedon ST, Loc-Carrillo C (2013) Phage cocktails and the future of phage therapy. Future Microbiol. 8, 769-783.
7. Bourguet D (2013) Heterogeneity of selection and the evolution of resistance. Trends Ecol. Evol. 28, 110-118.
8. Lu TK, Collins JJ (2009) Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc. Natl. Acad. Sci. USA 106, 4629-4634.
9. Escobar-Paramo P, Gougat-Barbera C, Hochberg ME (2012) Evolutionary dynamics of separate and combined exposure of Pseudomonas fluorescens SBW25 to antibiotics and bacteriophage. Evol. Appl. 5, 583-592.
10. Ward H, Perron GG, Maclean RC (2009) The cost of multiple drug resistance in Pseudomonas aeruginosa. J. Evol. Biol. 22, 997-1003.
11. Yeh PJ, Hegreness MJ, Aiden AP, Kishony R (2009) Drug interactions and the evolution of antibiotic resistance. Nat. Rev. Microbiol. 7, 460-466.
12. Michel J-B, Yeh PJ, Chait R, Moellering RC Jr, Kishony R (2008) Drug interactions modulate the potential for evolution of resistance. P. Natl. Acad. Sci. USA 105, 14918-14923.
13. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, et al. (2007) Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chem. 51, 3781-3788.
14. Zinner SH, Gilbert D, Greer K, Portnoy YK, Firsov AA (2013) Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model. J. Antimicrob. Chem. 68, 881-887.
15. Canton R, Morosini MI (2011) Emergence and spread of antibiotic resistance following exposure to antibiotics. Fems Microbiol. Rev. 35, 977-991.
16. Read AF, Day T, Huijben S (2011) The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. Proc. Natl. Acad. Sci. USA 108, 10871-10877.
17. Ryan EM, Gorman SP, Donnelly RF, Gilmore BF (2011) Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. J. Pharm. Pharmacol. 63, 1253-1264.
18. Levin BR, Bull JJ (1996) Phage therapy revisited: The population biology of a bacterial infection and its treatment with bacteriophage and antibiotics. Am. Nat. 147, 881-898.
19. Breidenstein EBM, de la Fuente-Nunez C, Hancock REW (2011) Pseudomonas aeruginosa : all roads lead to resistance. Trends Microbiol. 19, 419-426.
20. Zembower R, Noskin GA, Postelnick MJ, Nguyen N, Peterson LR (1998) The utility of aminoglycosides in an era of emerging drug resistance. Int. J. Antimicrob. Agents. 10 (2): 95-105.
21. Poole K (2005) Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrobial agents and Chemotherapy 49 (2): 479-487.
22. Ceyssens PJ, Brabban A, Rogge L, Lewis MS, Pickard D, et al. (2010) Molecular and physiological analysis of three Pseudomonas aeruginosa phages belonging to the "N4-like viruses". Virology 405, 26-30.
23. Betts A, Vasse M, Kaltz O, Hochberg ME (2013) Back to the future: evolving bacteriophages to increase their effectiveness against the pathogen Pseudomonas aeruginosa PAO1. Evol. Appl. 6, 1054-1063.
24. SAS. JMP statistics and graphics guide (version 10) (2012) In. SAS Institute Cary, N.C.
25. Arias CA, Murray BE (2009) Antibiotic-Resistant Bugs in the 21st Century - A Clinical Super-Challenge. New Engl. J. Med. 360, 439-443.
26. Zhang Q-G, Buckling A (2012) Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms. Evol. Appl. 5, 575-582.
27. Martin M, Aguilée R, Ramsayer J, Kaltz O, Ronce O (2013) The probability of evolutionary rescue: towards a quantitative comparison between theory and evolution experiments. Phil. Trans. R. Soc. B. 368, 20120088.
28. Kohanski MA, Dwyer DJ, Collins JJ (2010) How antibiotics kill bacteria: from targets to networks. Nat. Rev. Microbiol. 8, 423-435.
29. Ramsayer J, Kaltz O, Hochberg ME (2013) Evolutionary rescue in populations of Pseudomonas fluorescens across an antibiotic gradient. Evol. Appl. 6, 608-616.
30. Chait R, Craney A, Kishony R (2007) Antibiotic interactions that select against resistance. Nature 446, 668-671.
31. Hegreness M, Shoresh N, Damian D, Hartl D, Kishony R (2008) Accelerated evolution of resistance in multidrug environments. Proc. Natl. Acad. Sci. USA 105, 13977-13981.
32. Brockhurst MA, Buckling A, Rainey PB (2005) The effect of a bacteriophage on diversification of the opportunistic bacterial pathogen, Pseudomonas aeruginosa. Proc. Roy. Soc. B-biol. Sci. 272, 1385-1391.
33. Hall AR, Iles JC, MacLean RC (2011) The fitness cost of rifampicin resistance in Pseudomonas aeruginosa depends on demand for RNA polymerase. Genetics 187, 817-822.
34. Drenkard E, Ausubel FM (2002) Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation". Nature 416 (6882): 740-743.
35. Hall AR, De Vos D, Friman V-P, Pirnay J-P, Buckling A (2012) Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae. Appl. Environ. Microb. 78, 5646-5652.
36. Springer B, Kidan YG, Prammananan T, Ellrott K, Böttger EC, et al. (2001) Mechanisms of streptomycin resistance: Selection of mutations in the 16S rRNA gene conferring resistance. Antimicrob. Agents Chem. 45, 2877-2884.
37. Samson JE, Magadan AH, Sabri M, Moineau S (2013) Revenge of the phages: defeating bacterial defences. Nat. Rev. Microbiol. 11, 675-687.
38. De Paepe M, Taddei F (2006) Viruses' life history: Towards a mechanistic basis of a trade-off between survival and reproduction among phages. Plos Biol. 4, e193.
39. Cairns BJ, Timms AR, Jansen VAA, Connerton IF, Payne RJH (2009) Quantitative models of in vitro bacteriophage-host dynamics and their application to phage therapy. Plos Pathog. 5, e1000253.
40. Brown EM, Sadarangani M, Finlay BB (2013) The role of the immune system in governing host-microbe interactions in the intestine. Nat. Immunol. 14, 660-667.
41. Leggett HC, Cornwallis CK, West SA (2012) Mechanisms of pathogenesis, infective dose and virulence in human parasites. PLoS Pathog 8(2): e1002512.
42. Filippov AA, Sergueev KV, He Y, Huang XZ, Gnade BT, et al. (2011) Bacteriophage-resistant mutants in Yersinia pestis: identification of phage receptors and attenuation for mice. Plos One 6, e25486.
43. Fischbach MA (2011) Combination therapies for combating antimicrobial resistance. Curr. Opin. Microbiol. 14, 519-523.
44. Cottarel G, Wierzbowski J (2007) Combination drugs, an emerging option for antibacterial therapy. Trends Biotechnol. 25, 547-555.